// App-Quantinova.ai

8041 : LocoMMotion: A prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed/refractory multiple myeloma (RRMM) receiving ≥3 prior lines of therapy.

Researchers

Presenter

  • Maria-Victoria Mateos

Principal Investigators

  • Valerio De Stefano

  • Aurore Perrot

  • Niels W.C.J. van de Donk

  • Hartmut Goldschmidt

  • Martin F. Kaiser

  • Ravi Vij

  • Francesca Gay

  • Annemiek Broijl

  • Anna Potamianou

  • Caline Sakabedoyan

  • Vadim Strulev

  • Jordan Mark Schecter

  • Martin Vogel

  • Tonia Nesheiwat

  • Robert Wapenaar

  • Michel Delforge

  • Hermann Einsele

  • Philippe Moreau

Medical Centers

  • Hospital Universitario De Salamanca-IBSAL, Salamanca, Spain

  • University Medical Center Hamburg Eppendorf, Hamburg, Germany

  • Section of Hematology, Department of Radiological and Hematological Sciences,Catholic University, Fondazione Policlinico A. Gemelli, IRCCS,Roma,Italy

  • Institut Universitaire du Cancer de Toulouse, Toulouse, France

  • Amsterdam University Medical Center, Location VU University Medical Center, Amsterdam, Netherlands

  • University Hospital Heidelberg, Internal Medicine V and National Center for Tumor Diseases (NCT),Heidelberg,Germania

  • Institute for Cancer Research, London, United Kingdom

  • Washington University School of Medicine, St. Louis, MO, Division of Hematology, University of Torino, Torino, Italy

  • Department of Hematology, Erasmus MC Cancer Insitute, Rotterdam, Netherlands

  • Janssen-Cilag GmbH, Neuss, Germany

  • EMEA Medical Affairs, Janssen-Cilag, Beirut, Lebanon

  • EMEA Medical Affairs, Janssen Pharmaceutica, Beerse, Belgium

  • Janssen R&D, Raritan, NJ, Janssen Global Services, LLC, Raritan, NJ, Medical Affairs, Legend Biotech USA Inc, Piscataway, NJ, Janssen-Cilag BV, Breda, Netherlands

  • Department of Hematology, University Hospital Leuven, Leuven, Belgium

  • Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II,Würzburg,Deutschland

  • Hematology, University Hospital, Nantes, France

Locations

  • Spain

  • Germany

  • Italy

  • France

  • Netherlands

  • United Kingdom

  • Lebanon

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Non Interventional

  • Multinational

  • Prospective

Phase

  • N/A

Study Id's

  • NCT04035226

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved